Sixty-day antibiotic treatment not enough to prevent anthrax in some cases

The 60-day dose of antibiotics recommended by doctors to prevent anthrax may not be long enough in some cases, according to an analysis conducted by researchers at the Johns Hopkins Bloomberg School of Public Health. Mathematical analysis shows that prophylaxis antibiotics may be needed for as long as four months for people exposed to high levels of anthrax spores. The new model also provides a valuable tool for estimating exposure doses in future outbreaks that can then be used to determine the optimum window for antibiotic therapy. The analysis appears in the July 28, 2003, issue of the Proceedings of the National Academy of Sciences.

"Anthrax spores are expelled from the lungs at a specific rate. Our model calculates the time it takes the body to expel these spores. A single spore left behind can germinate to cause disease," explained Ron Brookmeyer, PhD, lead author of the study and professor of biostatistics at the School of Public Health. "The model we developed shows that larger exposures to anthrax spores take longer to expel and require longer antibiotic therapy. Sixty days of antibiotics provides adequate protection in outbreaks with low exposure to spores. However, four months of antibiotics are required for outbreaks in which persons are exposed to large numbers of spores."

Dr. Brookmeyer and his colleagues tested their model using data from the 2001 anthrax attack on the United States and the 1979 anthrax outbreak near a biological weapons plant in Sverdlovsk, Russia. In both cases, the model's predictions were consistent with the actual illness rates.

"During the 2001 U.S. anthrax attacks, many people failed to take the recommended 60-day course of antibiotics. Full compliance was about 60 percent or less in some cases. Our model showed that the reason they didn't get sick even without the antibiotics was because the anthrax spore exposure levels were very low. If the exposure levels were higher, there would have been more casu

Contact: Tim Parsons
Johns Hopkins University Bloomberg School of Public Health

Page: 1 2

Related biology news :

1. Anthrax enzyme images reveal secrets of antibiotic resistance, suggest new drug design
2. Smart antibiotics may result from UCLA research
3. K-State researcher working to improve alternatives to equine antibiotics
4. Bacterial protein recycling factor possible key to new class of antibiotics
5. Bacteria spill their guts to aid researchers in quest for new antibiotics
6. Molecule that blocks key bacterial enzyme may lead to new antibiotics
7. Does antibiotic use contribute to allergies?
8. Tigecycline - Candidate antibiotic produces 74 percent cure rate in cSSSI patients
9. Tigecycline - antibiotic evaluated in surveillance trial
10. Data show investigational antibiotic safe, effective in preventing travelers diarrhea
11. Chicken litter harbors agents that generate antibiotic multi-resistance, according to UGA study

Post Your Comments:

(Date:7/2/2020)... Calif. (PRWEB) , ... July 01, 2020 , ... ... company, presented its phase 1a findings of Neihulizumab, a biologic for the treatment ... in June 2020. Led by hemato-oncologist Dr. Paul J Martin of the Fred ...
(Date:7/1/2020)... ... July 01, 2020 , ... Cure Glioblastoma, a registered ... common and aggressive adult brain cancer—announced today the appointments of its first Senior ... with supporting the organization’s initiatives and overall vision. , "Senior Fellows are more ...
(Date:6/25/2020)... (PRWEB) , ... June 24, 2020 , ... ... cloud-based enterprise software and software-driven clinical data services that accelerate drug development, is ... low-dose selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... Va. (PRWEB) , ... July 08, 2020 , ... ... testing services and products, announces a significant expansion of laboratory operations through its ... collection for agencies implementing testing programs. , Bode-CARES provides a ...
(Date:7/10/2020)... LEXINGTON, Mass. (PRWEB) , ... July 09, 2020 ... ... novel approaches to cell therapy, today announced the hiring of Allen R. Nissenson, ... executive team and oversee the clinical development of Sentien’s lead product, SBI-101. ...
(Date:7/1/2020)... ... June 29, 2020 , ... ... date growth of 40% in 2020, despite many obstacles created as a result ... to increase revenue for its partnered medical practices and medical manufacturers by expanding ...
(Date:6/28/2020)... ... 25, 2020 , ... The Indoor Lab, a leading provider of sensor solutions ... all types to ensure cleanliness, distancing and occupancy with its patent pending WipeAway™ technology ... business will provide a health performance index system that scores all aspects of compliance ...
Breaking Biology Technology:
Cached News: